Loading
A phase 3 trial of Rilvegostomig, Durvalumab and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, now recruiting.
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) is a phase 3 interventional study registered as NCT07221253 by AstraZeneca, with 1100 participants planned, started 2025-12-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: Rilvegostomig, Durvalumab and Gemcitabine/Cisplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + cisplatin, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Gemcitabine + cisplatin, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Biliary tract cancer (cholangiocarcinoma), Immune checkpoint inhibitors and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/